Nasdaq
$2.83▼ 0.18%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $216.4MShares out 76.5M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
7- 2d agoAfter-hours26.10.23 05:2325-NSEOther#●●●#●●●
SAB Biotherapeutics, Inc.Bullish
SAB Biotherapeutics has been officially delisted and its registration removed from the Nasdaq Stock Market. The delisting of the securities became effective as of October 22, 2026.…more
$2.83-0.18%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.13Pre-market26.10.13 21:368-KKey event
SAB Biotherapeutics, Inc.
SAB Biotherapeutics announced that the FDA has granted Fast Track designation to its lead candidate, SAB-142, for the treatment of Stage 3 type 1 diabetes. This designation is expected to expedite the development and review process, with enrollment for the Phase 2b SAFEGUARD study concluding in Q4 2026 and topline data anticipated in 2H 2027.…more
$2.83-0.18%vs prev closeView filingShare - 9.18After-hours26.09.19 05:154Ownership
SAB Biotherapeutics, Inc.
SAB Biotherapeutics insider Alexandra Kropotova filed a Form 4 on September 18, 2026, reporting a change in beneficial ownership of securities as of September 17, 2026. This filing serves as a standard disclosure regarding the insider's equity holdings.…more
$2.83-0.18%vs prev closeView filingShare
6 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.14Pre-market26.10.14 21:30#●●●#●●●
SAB BIO to Participate in Chardan 10th Annual Healthcare Conference
SAB Biotherapeutics announced that its management team will participate in the upcoming Chardan 10th Annual Healthcare Conference. This event involves standard investor relations activities and does not provide immediate material impact on the stock price.…more
$2.83-0.18%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.13Pre-market26.10.13 21:30
●●●●●●●● ●●●●● ●●●●●●
SAB Biotherapeutics has been granted FDA Fast Track designation for its SAB-142 candidate for the treatment of Stage 3 type 1 diabetes. This regulatory milestone aims to expedite the development and review process for the therapy to address significant unmet medical needs.…more
$2.83-0.18%vs prev close - 10.1Pre-market26.10.01 21:30
●●●●●●●● ●●●●● ●●●●●●
SAB Biotherapeutics will present encore Phase 1 clinical data for its type 1 diabetes candidate, SAB-142, at the upcoming Breakthrough T1D Clinical & Research Congress. The presentation focuses on sharing existing safety and efficacy profiles rather than announcing new clinical milestones.…more
$2.83-0.18%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report